Comparison of Wear Between Two Dual-mobility Acetabular Cups in Patients Undergoing Total Hip Arthroplasty
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ECIMA CORIN, CORIN.
- Who it may be relevant to
- Registry conditions: Hip Arthroplasty Replacement. Basic parameters: 55 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
In 2022, data from the UK's National Joint Registry (NJR) and the American Joint Replacement Registry (AJRR) indicated that Total Hip Replacement (THR) is the most commonly performed orthopaedic joint surgery. The NJR has observed that between 10 and 20% of hip implants require revision within the first 10 years. The main reasons for these revisions include implant fractures, joint incompatibility, aseptic loosening, dislocation and wear of the polyethylene (PE) insert. To address this problem, highly cross-linked polyethylene (HXLPE) inserts have been developed. Cross-linking helps to limit wear on polyethylene prostheses in total hip arthroplasty. However, there are concerns about the loss of elasticity of HXLPE and oxidation after implantation. A new generation of inserts based on highly cross-linked polyethylene (irradiation dose ≥100 Kgy), enriched with vitamin E, has been developed. This PE, called ECIMA, was developed to maintain mechanical properties, minimise PE wear and improve long-term oxidation resistance. In the HAS evaluation report on highly cross-linked polyethylene inserts dated 24 January 2023, data from the literature show less wear of highly cross-linked polyethylene compared to conventional polyethylene. Nevertheless, the use of highly cross-linked polyethylene is not yet the gold standard. Furthermore, the data in the literature mainly concern single-mobility cups but not double-mobility cups. Finally, new imaging protocols now make it possible to assess the wear of prosthesis materials more accurately. In this context, it seems appropriate to conduct a French study comparing double-mobility cups containing highly cross-linked polyethylene or conventional polyethylene inserts.
Detailed description
In 2022, data from the UK's National Joint Registry (NJR) and the American Joint Replacement Registry (AJRR) indicated that total hip arthroplasty or Total Hip Replacement (THR) is the most commonly performed orthopaedic joint surgery.
THR involves replacing worn and damaged areas of cartilage in the hip with artificial parts of similar shape and size. A total hip replacement consists of two parts:
* A part designed to replace the head of the femur: a spherical prosthesis mounted on a stem that is inserted into the femur; * A part designed to replace the acetabulum: the acetabular cup. There are single-mobility cups and double-mobility cups, where an insert is positioned on the metal head inside a single-mobility cup. Introduced in the 1960s by Sir John Charnley, UHMWPE (Ultra High Molecular Weight Polyethylene) remains the most widely used material for inserts in 2024.
The NJR has observed that between 10 and 20% of hip implants require revision within the first 10 years. The main reasons for these revisions include implant fractures, joint incompatibility, aseptic loosening, dislocation and wear of the polyethylene (PE) insert.
To address this problem, highly cross-linked polyethylene (HXLPE) inserts have been developed. Cross-linking helps to limit wear on polyethylene prostheses in total hip arthroplasty. However, there are concerns about the loss of elasticity of HXLPE and oxidation after implantation.
A new generation of inserts based on highly cross-linked polyethylene (irradiation dose ≥100 Kgy), enriched with vitamin E, has been developed. This PE, called ECIMA, was developed to maintain mechanical properties, minimise PE wear and improve long-term oxidation resistance.
In the HAS evaluation report on highly cross-linked polyethylene inserts dated 24 January 2023, data from the literature show less wear of highly cross-linked polyethylene compared to conventional polyethylene.
Nevertheless, the use of highly cross-linked polyethylene is not yet the gold standard. Furthermore, the data in the literature mainly concern single-mobility cups but not double-mobility cups. Finally, new imaging protocols now make it possible to assess the wear of prosthesis materials more accurately.
In this context, it seems appropriate to conduct a French study comparing double-mobility cups containing highly cross-linked polyethylene or conventional polyethylene inserts.
In the principal investigator's current practice, prostheses with conventional PE inserts are used for patients aged 70 or over, while prostheses with highly cross-linked PE inserts are used for patients under 70. However, this age-based choice is modulated favourably or unfavourably by two other parameters: the patient's medical history and general condition.
Interventions
- Device ECIMA CORIN
Mobile cup (Corin) made of highly cross-linked PE doped with vitamin E (ECIMA, Corin). - Device CORIN
Mobile cupule (Corin) is made of conventional PE
Primary outcome measures
- Femoral head penetration into the acetabulum [Time frame: Year 5]
Eligibility criteria
Inclusion criteria
- Patient, male or female, aged between 55 and 80.
- Patient with a life expectancy > 5 years at the time of inclusion.
- Patient scheduled to undergo primary total hip arthroplasty with a dual-mobility cup prosthesis.
- Patient affiliated with or beneficiary of a social security scheme.
- Patient who speaks French and has signed an informed consent form.
Exclusion criteria
- Patients with a contraindication mentioned in the instructions for use of the medical device under investigation
- Patients with an ASA score of 4
- Protected patients: adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision
- Patients participating in another clinical study whose objectives could interfere with this study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
France · 1 center
- Hôpital Privé Jean Mermoz — Lyon
Identifiers
NCT: NCT07207005 · 2024-A02615-42